- A new study from the University of Pennsylvania Perelman School of Medicine found that women taking GLP-1 weight loss drugs like Ozempic and Wegovy had a 30 percent reduced risk of developing breast cancer.
- These findings build on previous research linking GLP-1 use to improved outcomes for various cancers, suggesting a broader potential for cancer prevention.
- The observational study analyzed health data from over 110,000 overweight American women aged 45 to 80 between 2022 and 2025, with 15,264 participants initially using GLP-1 medications.
- Researchers, including Dr. Elizabeth McDonald, emphasize that while the study does not definitively confirm a direct association, it warrants further investigation into these drugs as cancer prevention tools.
- The potential mechanisms behind this reduced risk include the drugs' ability to promote weight loss and reduce inflammation, both of which are known risk factors for breast cancer.
IN FULL
